Nippon Chemiphar : First quarter business summary FY2023.

（TSE 4539）

FY2023 First Quarter Business Summary

(Year Ending March 31, 2024)

Sales, Income

							(¥mn)
	FY2022			FY2023		FY2023 Forecast
1Q	% of	Full Year	1Q	% of	YOY	Full Year	Progress
Amount	Sales	Amount	Amount	Sales	(%)	Amount	Rate (%)

Net sales	8,425	100.0	31,559	7,537	100.0	(10.5)	32,700	23.0
Pharmaceutical Products segment	8,214	97.5	30,543	7,299	96.8	(11.1)		―	―
Generics, proprietary products
and new drugs	7,129	84.6	26,148	6,010	79.7	(15.7)	25,870	23.2
Diagnostics	601	7.1	2,780	924	12.3	53.6	4,500	20.5
Others segment	210	2.5	1,015	237	3.2	12.8		―	―
Cost of sales		6,200	73.6		23,374		5,686	75.4	(8.3)		―	―
SG&A expenses		2,050	24.3		8,425		1,957	26.0	(4.5)		―	―
R&D expenses	445	5.3	2,419	463	6.2	4.0	2,820	16.4
Operating income/loss		175	2.1		(241)		(106)	―	―		200	―
Ordinary profit		514	6.1		58		111	1.5	(78.2)		100	112.0
Net profit attributable to
owners of parent		653	7.8		339		79	1.1	(87.8)		60	132.5

1

Pharmaceutical Sales

Generics, Proprietary Products and New Drugs								(¥mn)
				FY2022			FY2023			FY2023 Forecast
			1Q	Distrib.	Full Year	1Q	Distrib.	YOY		Full Year	Progress
			Amount	(%)	Amount	Amount	(%)	(%)		Amount	Rate (%)
Total		7,129	100.0	26,148	6,010	100.0	(15.7)	25,870	23.2
Generics		6,772	95.0	24,803	5,674	94.4	(16.2)	24,640	23.0
To medical institutions	6,524		23,698	5,460		(16.3)	23,830	22.9
To other makers*	247		1,105	213		(13.5)	810	26.4
Proprietary products and new drugs	357	5.0	1,345	336	5.6	(5.9)	1,230	27.3
	Uralyt		149		575	135		(9.3)	530	25.6
	Others	208		769	200		(3.5)	700	28.7
Chemiphar, ODM Generics										(¥mn)
				FY2022			FY2023			FY2023 Forecast
			1Q	Distrib.	Full Year	1Q	Distrib.	YOY		Full Year	Progress
			Amount	(%)	Amount	Amount	(%)	(%)		Amount	Rate (%)
Total		7,135	100.0	25,881	5,916	100.0	(17.1)	25,670	23.0
Generics		6,772	94.9	24,803	5,674	95.9	(16.2)	24,640	23.0
Generics (ODM)		363	5.1	1,078	242	4.1	(33.4)	1,030	23.5

* Includes exports.

2

Sales Distribution

By Launch Year						(¥mn)
		FY2022		FY2023
		1Q	Distrib.	1Q	Distrib.	YOY
		Amount	(%)	Amount	(%)	(%)
FY2016 and before		5,585	82.5	4,421	77.9	(20.8)
FY2017		410	6.1	373	6.6	(8.8)
FY2018		224	3.3	173	3.1	(22.9)
FY2019		35	0.5	39	0.7	11.1
FY2020		361	5.3	270	4.8	(25.1)
FY2021		110	1.6	93	1.7	(15.6)
FY2022		43	0.6	233	4.1	430.9
FY2023		―	―	69	1.2	―
Total		6,772	100.0	5,674	100.0	(16.2)

By Main Therapeutic Categories			(%)
		FY2022		FY2023
		1Q		1Q
Cardiovascular and respiratory drugs	27.5	26.3
Agents affecting metabolism	17.0	18.1
Digestive organ drugs	15.1	15.4
Drugs for nervous system, sensory organs	13.8	12.0
Antibiotics and chemotherapeutic drugs	4.6	3.4
Antineoplastic agents	1.9	2.0
Others	20.1	22.8

3

Balance Sheet, per Share Information

	Balance Sheet Data								(¥mn)
			March 31, 2023		June 30, 2023
			Amount		Amount	Change
	Total assets	48,571	52,078				3,506
	Net assets	18,534	18,393				(140)
	Owned capital	18,517	18,376				(140)
	Equity ratio (%)	38.1	35.3				(2.8)
	Current assets	33,436	35,926				2,489
	Current liabilities	14,766	15,803				1,036
	Current ratio (x)	2.26	2.27				0.01
	Per ShareInformation												(¥)
			FY2022						FY2023
			1Q		Full Year				1Q			Full Year
			Amount		Amount				Amount	YOY	(Forecast)
	Earnings per share	180.91	94.07			22.03	(158.88)		16.62
													Full Year
			June 30, 2022		March 31, 2023				June 30, 2023	Change	(Forecast)
	Book value per share		5,150.78	5,130.65			5,091.84	(58.94)		―
	Dividend per share		―	50.00				―	―	50.00
	Dividend payout ratio (%)		―	53.2				―	―	300.8

4